HK1223968A1 - 狂犬病病毒組合物和方法 - Google Patents

狂犬病病毒組合物和方法

Info

Publication number
HK1223968A1
HK1223968A1 HK16111244.3A HK16111244A HK1223968A1 HK 1223968 A1 HK1223968 A1 HK 1223968A1 HK 16111244 A HK16111244 A HK 16111244A HK 1223968 A1 HK1223968 A1 HK 1223968A1
Authority
HK
Hong Kong
Prior art keywords
compositions
methods
rabies virus
rabies
virus
Prior art date
Application number
HK16111244.3A
Other languages
English (en)
Inventor
查爾斯
．盧普里希
吳賢福
Original Assignee
The Government Of The United States Of America As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America As filed Critical The Government Of The United States Of America As
Publication of HK1223968A1 publication Critical patent/HK1223968A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK16111244.3A 2005-10-14 2008-12-17 狂犬病病毒組合物和方法 HK1223968A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72703805P 2005-10-14 2005-10-14

Publications (1)

Publication Number Publication Date
HK1223968A1 true HK1223968A1 (zh) 2017-08-11

Family

ID=37775467

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16111244.3A HK1223968A1 (zh) 2005-10-14 2008-12-17 狂犬病病毒組合物和方法
HK08113710.4A HK1123326A1 (zh) 2005-10-14 2008-12-17 狂犬病病毒組合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08113710.4A HK1123326A1 (zh) 2005-10-14 2008-12-17 狂犬病病毒組合物和方法

Country Status (9)

Country Link
US (2) US7863041B2 (zh)
EP (2) EP2351843B1 (zh)
CN (1) CN101287838B (zh)
AU (1) AU2006304268B2 (zh)
BR (1) BRPI0617373B1 (zh)
CA (2) CA2943039C (zh)
HK (2) HK1223968A1 (zh)
WO (1) WO2007047459A1 (zh)
ZA (1) ZA200803131B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8748567B2 (en) 2006-05-22 2014-06-10 Children's Medical Center Corporation Method for delivery across the blood brain barrier
PL2139515T5 (pl) 2007-03-30 2024-04-08 The Research Foundation Of The State University Of New York Atenuowane wirusy przydatne w szczepionkach
US8524247B2 (en) 2008-09-17 2013-09-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Rabies virus-based recombinant immunocontraceptive compositions and methods of use
CN101463355B (zh) * 2009-01-15 2011-07-13 中国疾病预防控制中心病毒病预防控制所 狂犬病街毒株hn10全基因组序列及其制备方法和用途
CN101586120B (zh) * 2009-07-15 2011-06-15 中国农业科学院哈尔滨兽医研究所 狂犬病病毒Flury-LEP疫苗株反向遗传操作系统及LEP绿色荧光蛋白重组病毒载体
PL2491117T3 (pl) * 2009-10-20 2014-05-30 Novartis Ag Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę
WO2013081571A2 (en) * 2010-01-14 2013-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Isolated lyssavirus nucleic acid and protein sequences
US9248179B2 (en) * 2010-06-24 2016-02-02 The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Pan-lyssavirus vaccines against rabies
CN103492574B (zh) * 2011-02-22 2015-12-09 加州理工学院 使用腺相关病毒（aav）载体递送蛋白
US9441205B2 (en) 2011-06-08 2016-09-13 Vishwas Joshi Two plasmid mammalian expression system
CN103906843B (zh) * 2011-06-08 2016-12-07 维什瓦斯·乔希 双质粒哺乳动物表达系统
US8689255B1 (en) 2011-09-07 2014-04-01 Imdb.Com, Inc. Synchronizing video content with extrinsic data
WO2014055289A1 (en) * 2012-10-01 2014-04-10 Thomas Jefferson University Immunization with rabies virus vector expressing foreign protein antigen
US20160251680A1 (en) 2013-11-05 2016-09-01 Clontech Laboratories, Inc. Dry transfection compositions and methods for making and using the same
CN103881985B (zh) * 2014-02-19 2017-10-03 北京中联康生物科技股份有限公司 狂犬病病毒era减毒疫苗突变株及其制备方法和狂犬病活疫苗
CN103877570B (zh) * 2014-02-19 2016-01-20 北京中联康生物科技有限公司 狂犬病活疫苗和制备狂犬病口服活疫苗的方法
RU2626605C2 (ru) * 2015-11-25 2017-07-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Генетическая (рекомбинантная) ДНК-конструкция, содержащая кодон-оптимизированный ген гликопротеина (белка G) вируса бешенства с консенсусной аминокислотной последовательностью, которая составлена с учетом аминокислотных последовательностей белка G, выделяемого из штаммов вируса бешенства, циркулирующих на территории Российской Федерации
KR102334083B1 (ko) * 2020-05-04 2021-12-03 대한민국 형광 단백질을 발현하는 재조합 광견병 바이러스 및 이를 이용한 항체 검출 방법

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4040904A (en) 1975-07-21 1977-08-09 Slater Eban A Novel rabies virus vaccine and processes
US4393201A (en) 1981-11-04 1983-07-12 The Wistar Institute DNA Which codes for glycoprotein of era-strain rabies virus
CA1323293C (en) 1987-12-11 1993-10-19 Keith C. Backman Assay using template-dependent nucleic acid probe reorganization
FR2633832B1 (fr) 1988-07-05 1991-05-31 Virbac Vaccin antirabique avirulent
EP0425563B1 (en) 1988-07-20 1996-05-15 David Segev Process for amplifying and detecting nucleic acid sequences
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
FR2693655B1 (fr) 1992-07-20 1994-10-14 Virbac Vaccin antirabique avirulent.
WO1994027639A1 (en) 1993-05-26 1994-12-08 Thomas Jefferson University Methods for treating post-exposure rabies and anti-rabies compositions
WO1995009249A1 (en) 1993-09-30 1995-04-06 Thomas Jefferson University Oral vaccination of mammals
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
KR100392551B1 (ko) 1994-07-15 2003-10-30 아크조 노벨 엔브이 핵산 증폭방법을 개선시키기 위한 rna폴리머라제의 용도
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5789229A (en) 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
WO2002036170A2 (en) * 2000-11-03 2002-05-10 Oxford Biomedica (Uk) Limited Vector system for transducing the positive neurons
EP1131414B1 (en) 1998-11-27 2007-03-07 Intervet International BV Stable, attenuated rabies virus mutants and live vaccines thereof
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7074413B2 (en) 2000-03-23 2006-07-11 Thomas Jefferson University Genetically engineered rabies recombinant vaccine for immunization of stray dogs and wildlife
ES2257505T3 (es) 2001-04-23 2006-08-01 Akzo Nobel N.V. Mutantes de virus de la rabia atenuados y vacunas vivas correspondientes.
AU2002365029A1 (en) 2001-07-20 2003-06-10 The University Of Georgia Research Foundation, Inc. Attenuated rabies virus with nucleoprotein mutation at the phosphorylation site for vaccination against rabies
US7223584B2 (en) 2001-10-10 2007-05-29 Thomas Jefferson University Recombinant rabies vaccine and methods of preparation and use
US9912298B2 (en) 2014-05-13 2018-03-06 Skyworks Solutions, Inc. Systems and methods related to linear load modulated power amplifiers

Also Published As

Publication number Publication date
CA2943039A1 (en) 2007-04-26
BRPI0617373A2 (pt) 2013-01-01
CA2624768C (en) 2016-10-04
CN101287838B (zh) 2016-03-30
CA2624768A1 (en) 2007-04-26
AU2006304268A1 (en) 2007-04-26
WO2007047459A8 (en) 2007-09-20
CA2943039C (en) 2018-11-06
BRPI0617373B1 (pt) 2022-04-05
US20110070264A1 (en) 2011-03-24
AU2006304268B2 (en) 2011-09-29
EP2351843B1 (en) 2013-06-12
WO2007047459A1 (en) 2007-04-26
CN101287838A (zh) 2008-10-15
US8865461B2 (en) 2014-10-21
ZA200803131B (en) 2018-11-28
US20080274130A1 (en) 2008-11-06
EP2351843A3 (en) 2011-11-09
EP1945780A1 (en) 2008-07-23
AU2006304268A2 (en) 2008-06-12
EP2351843A2 (en) 2011-08-03
US7863041B2 (en) 2011-01-04
HK1123326A1 (zh) 2009-06-12
EP1945780B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
HK1223968A1 (zh) 狂犬病病毒組合物和方法
EP1895838A4 (en) COMPOSITIONS AND METHODS
IL198248A0 (en) Hepatitis c virus inhibitors and compositions comprising the same
GB0522287D0 (en) Method and compositions
EP1954708A4 (en) METHODS AND COMPOSITIONS IN INTRINSIC GENES
IL184111A0 (en) Prostaglandin-containing compositions and methods for enhancing the stability thereof
IL190259A0 (en) Compositions and methods comprising panax species
IL181543A0 (en) Dendrimer based compositions and methods of using the same
EP2086318A4 (en) NEUROPROTEKTIVE COMPOSITIONS AND METHOD
IL191072A0 (en) Therapeutic compositions and methods
ZA200709518B (en) Vaccine composition
IL193392A0 (en) Influenza antibodies, compositions, and related methods
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
EP1773386A4 (en) VACCINE COMPOSITIONS AND CORRESPONDING METHODS
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1991237A4 (en) CHEMOPROTECTIVE METHODS AND COMPOSITIONS
IL190239A0 (en) Pharmaceutical gallium compositions and methods
IL184834A0 (en) Compositions and methods for the manufacture thereof
EP1920064A4 (en) COMPOSITIONS AND METHODS FOR INCREASING AMPLIFICATION EFFICIENCY
GB0617171D0 (en) Novel compositions and methods
EP1848438A4 (en) DIAMINOPHENOTHIAZINE COMPOSITIONS AND THEIR USE
EP1929050A4 (en) COMPOSITIONS AND METHODS FOR DETECTING VIRUSES THEREWITH
GB0524927D0 (en) Compositions and method
ZA200805079B (en) Immunostimulatory compositions and methods
GB0416487D0 (en) Modified virus